The contract establishes Holmes Biopharma with another major multinational pharmaceutical company, generating substantial phase I clinical trial revenue for the Omaha operation. Furthermore, this contract is a significant revenue source for Holmes Biopharma’s Data Management Center in Toronto, Canada.
John Metcalfe, president and CEO of Holmes Biopharma, said: “We are just beginning to realize the potential of this highly profitable component of the clinical research business.”